Victory Capital Management Inc Travere Therapeutics, Inc. Transaction History

Victory Capital Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$22.91 - $28.63 $25,017 - $31,263	-1,092 Reduced 5.86%	17,547 $432,000
Q2 2022 Aug 01, 2022	BUY	$20.94 - $30.01 $10,051 - $14,404	480 Added 2.64%	18,639 $452,000
Q1 2022 May 04, 2022	BUY	$23.61 - $30.6 $245,780 - $318,546	10,410 Added 134.34%	18,159 $456,000
Q4 2021 Feb 07, 2022	BUY	$24.34 - $31.17 $188,610 - $241,536	7,749 New	7,749 $241,000
Q2 2021 Aug 03, 2021	SELL	$14.11 - $26.4 $121,458 - $227,251	-8,608 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$23.37 - $31.77 $201,168 - $273,476	8,608 New	8,608 $215,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.